A Case of Papillary Thyroid Carcinoma Undergoing Anaplastic Transformation During Long-term Treatment with Lenvatinib Which Responded to Pembrolizumab
Practica Oto-Rhino-Laryngologica · 2026 · 119 (11) · 739-745
DOI: 10.5631/jibirin.119.739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practica Oto-Rhino-Laryngologica, 2026. Verfasst von Satoshi Itoyama und 6 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Herein, we present a rare case of papillary thyroid carcinoma (PTC) that underwent anaplastic transformation during lenvatinib (LEN) therapy and showed a marked and sustained response to treatment with pembrolizumab (PEM). A 70-year-old woman diagnosed as having PTC, stage cT3N1bM0 was treated by total thyroidectomy and left neck dissection. She developed nodal recurrences at 3 and 5 years postoperatively, which were managed by surgical resection and radioiodine therapy. Upon recurrence of mediastinal and cervical nodal disease, the patient was initiated on LEN therapy, which yielded stable disease control for six years. Subsequently, the patient developed a rapidly enlarging cervical mass with vertebral invasion, which led to extraramural hypopharyngeal and esophageal narrowing. An open biopsy identified squamous cell carcinoma, and the lesion was initially diagnosed as unresectable hypopharyngeal cancer. Further staging workup revealed pulmonary and hepatic metastases. The programmed death-ligand 1 (PD-L1) combined positive score (CPS) was 100, and genomic profiling revealed BRAFV600E and PIK3CA mutations. The patient was initiated on PEM monotherapy following palliative vertebral irradiation. In response to this treatment, the cervical tumor showed marked regression, and the pulmonary and hepatic lesions almost completely disappeared, with the response sustained for over 27 months. Retrospective analysis confirmed BRAFV600E positivity in the original thyroid carcinoma, supporting anaplastic transformation of the primary thyroid carcinoma rather than a second primary malignancy. Immunohistochemical analysis of the anaplastically transformed tumor revealed high PD-L1 expression and dense CD8+ T-cell infiltration, in contrast to the case in the original tumor, suggesting a shift toward an “inflamed” tumor immune micro-environment (TIME). This case highlights the possibility that prolonged LEN exposure and/or tumor dedifferentiation may remodel the TIME, thereby enhancing the tumor susceptibility to immune checkpoint inhibitor therapy.
Zitieren
APA
Itoyama, S., Sato, F., Mitsuhashi, T., Watanabe, S., Ono, T., Chitose, S., & Umeno, H. (2026). A Case of Papillary Thyroid Carcinoma Undergoing Anaplastic Transformation During Long-term Treatment with Lenvatinib Which Responded to Pembrolizumab. Practica Oto-Rhino-Laryngologica, 119(11), 739-745. https://doi.org/10.5631/jibirin.119.739
Vancouver
Itoyama S, Sato F, Mitsuhashi T, Watanabe S, Ono T, Chitose S, et al. A Case of Papillary Thyroid Carcinoma Undergoing Anaplastic Transformation During Long-term Treatment with Lenvatinib Which Responded to Pembrolizumab. Practica Oto-Rhino-Laryngologica. 2026;119(11):739-745. doi:10.5631/jibirin.119.739
BibTeX
@article{Itoyama2026,
author = {Itoyama, Satoshi and Sato, Fumihiko and Mitsuhashi, Toshiyuki and Watanabe, Sachi and Ono, Takeharu and Chitose, Shunichi and Umeno, Hirohito},
title = {A Case of Papillary Thyroid Carcinoma Undergoing Anaplastic Transformation During Long-term Treatment with Lenvatinib Which Responded to Pembrolizumab},
journal = {Practica Oto-Rhino-Laryngologica},
year = {2026},
volume = {119},
number = {11},
pages = {739--745},
doi = {10.5631/jibirin.119.739}
}
EUVIMED